Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study

Bone Marrow Transplantation

Volumn 45, Issue 12, 2010, Pages 1704-1709

  Jordan, K ^a   Wolf, H H ^a   Voigt, W ^a   Kegel, T ^a   Mueller, L P ^a   Behlendorf, T ^a   Sippel, C ^a   Arnold, D ^a   Schmoll, H J ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

bevacizumab; germ cell cancer; high dose chemotherapy; sarcoma

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; ANEMIA; ANGIOSARCOMA; ARTICLE; ASTHENIA; BLEEDING; BRAIN DISEASE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHONDROSARCOMA; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EPITHELIOID SARCOMA; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GERM CELL TUMOR; HEMANGIOPERICYTOMA; HUMAN; HYPERTENSION; INCIDENCE; LEIOMYOSARCOMA; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; OSTEOSARCOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SARCOMA; SKIN TOXICITY; SPINDLE CELL SARCOMA; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VEIN THROMBOSIS; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; ETOPOSIDE; FEASIBILITY STUDIES; FEMALE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SARCOMA; YOUNG ADULT;

EID: 78650206321     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.50     Document Type: Article

References (29)

1. Pedrazzoli P, Ledermann J, Lotz JP, Leyvraz S, Aglietta M, Rosti G et al. High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. Ann Oncol 2006; 17: 1479-1488.
2. Maurel J, Lopez-Pousa A, de Las Penas R, Fra J, Martin J, Cruz J et al. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with adVanced soft tissue sarcoma: An open-label randomized phase II study of the Spanish group for research on sarcomas. J Clin Oncol 2009; 27: 1893-1898.
3. Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M. Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of adVanced or metastatic adult soft tissue sarcoma: A systematic review. Cancer 2008; 112: 1197-1205.
4. Kasper B, Lehnert T, Bernd L, Mechtersheimer G, Goldschmidt H, Ho AD et al. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant 2004; 34: 37-41.
5. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F et al. European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. Eur Urol 2008; 53: 497-513.
6. Schmoll HJ, Jordan K, Huddart R, Laguna MP, Horwich A, Fizazi K et al. Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20: 89-96.
7. Sharkey RM, GolDenberg DM. Targeted therapy of cancer: New prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006; 56: 226-243.
8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
9. Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG, Eisenberg B. Vascular endothelial growth factor and soft tissue sarcomas: Tumor expression correlates with grade. Ann Surg Oncol 2001; 8: 260-267.
10. Zhang L, Hannay JA, Liu J, Das P, Zhan M, Nguyen T et al. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: Implications for tumor growth, metastasis, and chemoresistance. Cancer Res 2006; 66: 8770-8778.
11. D'Adamo DR, Anderson SE, Albritton K, Yamada J, Riedel E, Scheu K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005; 23: 7135-7142.
12. Fukuda S, Shirahama T, Imazono Y, Tsushima T, Ohmori H, Kayajima T et al. Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer 1999; 85: 1323-1330.
13. Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88: 1979-1986.
14. Blay JY, Bouhour D, Ray-Coquard I, Dumontet C, Philip T, Biron P. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for adVanced soft tissue sarcoma in adults. J Clin Oncol 2000; 18: 3643-3650.
15. Hildebrand J. Neurological complications of cancer chemotherapy. Curr Opin Oncol 2006; 18: 321-324.
16. Sweiss KI, Beri R, Shord SS. Encephalopathy after high-dose Ifosfamide: A retrospective cohort study and review of the literature. Drug Saf 2008; 31: 989-996.
17. David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol 2005; 28: 277-280.
18. Glusker P, Recht L, Lane B, Ozcan C, Wong SJ, Hari P et al. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006; 354: 980-982.
19. Schiff D, Wen PY, Van Den Bent MJ. Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol 2009; 6: 596-603.
20. Schiff D, Purow B. Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme. Nat Clin Pract Oncol 2008; 5: 186-187.
21. VreDenburgh JJ, Desjardins A, Herndon II JE, Marcello J, Reardon DA, Quinn JA et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-4729. (Pubitemid 350086473)
22. Voigt W, Kegel T, Maher G, Jordan K, Muller L, Schmoll HJ. Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer. Ann Oncol 2006; 17: 531-533.
23. Schlemmer M, Wendtner CM, Falk M, Abdel-Rahman S, Licht T, Baumert J et al. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. Oncology 2006; 71: 32-39.
24. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345. (Pubitemid 38944402)
25. Baker LH, Rowinsky EK, Mendelson D, Humerickhouse RA, Knight RA, Qian J et al. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with adVanced soft tissue sarcoma. J Clin Oncol 2008; 26: 5583-5588.
26. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27: 3133-3140.
27. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory adVanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27: 3126-3132.
28. Verweij J. Soft tissue sarcoma trials: One size no longer fits all. J Clin Oncol 2009; 27: 3085-3087.
29. Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O et al. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Clin Cancer Res 2009; 15: 3384-3395.